In vitro toxicity assay of cisplatin on mouse acute lymphoblastic leukaemia and spermatogonial stem cells

Shabani, R. and Ashtari, K. and Behnam, B. and Izadyar, F. and Asgari, H. and Asghari Jafarabadi, M. and Ashjari, M. and Asadi, E. and Koruji, M. (2016) In vitro toxicity assay of cisplatin on mouse acute lymphoblastic leukaemia and spermatogonial stem cells. Andrologia, 48 (5). pp. 584-594.

Full text not available from this repository.
Official URL:


Summary: Testicular cancer is the most common cancer affecting men in reproductive age, and cisplatin is one of the major helpful chemotherapeutic agents for treatment of this cancer. In addition, exposure of testes cancer cells to cisplatin could potentially eliminate tumour cells from germ cells in patients. The aim of this study was to evaluate the effect of cisplatin on viability of mouse acute lymphoblastic leukaemia cell line (EL-4) and neonatal mouse spermatogonial cells in vitro. In this study, the isolated spermatogonial stem cells (SSC) and EL-4 were divided into six groups including control (received medium), sham (received DMSO in medium) and experimental groups which received different doses of cisplatin (0.5, 5, 10 and 15 μg ml-1). Cells viability was evaluated with MTT assay. The identity of the cultured cells was confirmed by the expression of specific markers. Our finding showed that viability of both SSC and EL-4 cells was reduced with the dose of 15 μg/ml when compared to the control group (P � 0.05). Also, the differences between the IC50 in doses 10 and 15 μg/ml at different time were significant (P � 0.05). The number of TUNEL-positive cells was increased, and the BAX and caspase-3 expressions were upregulated in EL4 cells for group that received an effective dose of cisplatin). In conclusion, despite the dramatic effects of cisplatin on both cells, spermatogonial stem cells could form colony in culture. © 2016 Blackwell Verlag GmbH.

Item Type: Article
Additional Information: cited By 4
Depositing User: eprints admin
Date Deposited: 04 Jul 2018 10:06
Last Modified: 04 Jul 2018 10:06

Actions (login required)

View Item View Item